A comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formation
- PMID: 9669660
- DOI: 10.1089/oli.1.1998.8.227
A comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formation
Abstract
Phosphorothioate oligodeoxynucleotides (PS oligos) manifest antisense and G-quartet aptameric inhibitory effects on vascular smooth muscle cell (SMC) proliferation. PS oligo cytidine homopolymers also have nonsequence-specific, non-G-quartet inhibitory effects on in vitro and in vivo SMC proliferation. In this study, we compared the effects of S-dC18 and S-dC28, 18-mer and 28-mer cytidine homopolymers, respectively, which lack guanosines, with those of ZK10, a G-tetrad forming compound, on in vitro SMC proliferation and in vivo neointimal formation. ZK10 significantly inhibited in vitro human aortic SMC proliferation. At the same molar concentration, ZK10 had significantly greater inhibitory potency on SMC proliferation than either S-dC18, S-dC28, or 7DG-ZK10, which is a modified ZK10 with ten 7-deaza guanosine substitutions. ZK10 was significantly more potent than S-dC18 and S-dC28 in inhibiting PDGF-induced in vitro SMC migration. S-dC18, S-dC28, and ZK10 treatment significantly reduced the intima/media area ratio after rat carotid artery balloon injury compared with the values of the control groups. ZK10 was a more potent inhibitor of neointimal formation than the same chain length S-dC18. ZK10 formed higher-order structures, as shown on gel electrophoresis, in contrast to S-dC28 and 7DG-ZK10. Therefore, the 18-mer ZK10 has comparable in vivo SMC inhibitory effects to the 28-mer S-dC28, a fact that may have ramifications for the development of optimal PS oligos to inhibit angioplasty restenosis.
Similar articles
-
Inhibitory nonsequence-specific effects of cytidine homopolymers on in vivo neointimal formation.Antisense Nucleic Acid Drug Dev. 1997 Dec;7(6):559-66. doi: 10.1089/oli.1.1997.7.559. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9450913
-
Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides.J Clin Invest. 1996 Jul 15;98(2):443-50. doi: 10.1172/JCI118810. J Clin Invest. 1996. PMID: 8755655 Free PMC article.
-
Antisense strategies to inhibit restenosis.Antisense Nucleic Acid Drug Dev. 1999 Oct;9(5):487-92. doi: 10.1089/oli.1.1999.9.487. Antisense Nucleic Acid Drug Dev. 1999. PMID: 10555157 Review.
-
Effects of S-dC28 on vascular smooth muscle cell adhesion and plasminogen activator production.Antisense Nucleic Acid Drug Dev. 1997 Apr;7(2):101-7. doi: 10.1089/oli.1.1997.7.101. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9149845
-
Porous balloon delivery of S-dC28 does not prevent restenosis in the porcine coronary artery model of balloon injury.Antisense Nucleic Acid Drug Dev. 1999 Dec;9(6):549-53. doi: 10.1089/oli.1.1999.9.549. Antisense Nucleic Acid Drug Dev. 1999. PMID: 10645782
Cited by
-
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.Exp Mol Pathol. 2009 Jun;86(3):151-64. doi: 10.1016/j.yexmp.2009.01.004. Epub 2009 Jan 20. Exp Mol Pathol. 2009. PMID: 19454272 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous